A combination antiretroviral intended to manage HIV-1 infection and developed to alleviate viral load by targeting replication to support immune system preservation.
Mechanism of Action
Lopinavir inhibits the HIV protease enzyme needed for viral maturation. Ritonavir acts as a booster by inhibiting the metabolism of lopinavir, maintaining higher drug levels.
Route of Administration
Oral
Onset Time
Steady state in 2 weeks
Duration
12 hours
Contraindications
Severe liver disease, Use of medications highly dependent on CYP3A for clearance, Allergy to lopinavir or ritonavir
Severe Adverse Events
Severe liver problems, Pancreatitis, Heart rhythm changes, Severe skin reactions, Diabetes
Information for Kaletra is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
